1. Home
  2. RGEN vs BXSL Comparison

RGEN vs BXSL Comparison

Compare RGEN & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • BXSL
  • Stock Information
  • Founded
  • RGEN 1981
  • BXSL 2018
  • Country
  • RGEN United States
  • BXSL United States
  • Employees
  • RGEN N/A
  • BXSL N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • BXSL Trusts Except Educational Religious and Charitable
  • Sector
  • RGEN Health Care
  • BXSL Finance
  • Exchange
  • RGEN Nasdaq
  • BXSL Nasdaq
  • Market Cap
  • RGEN 8.0B
  • BXSL 7.5B
  • IPO Year
  • RGEN N/A
  • BXSL N/A
  • Fundamental
  • Price
  • RGEN $128.04
  • BXSL $31.19
  • Analyst Decision
  • RGEN Buy
  • BXSL Buy
  • Analyst Count
  • RGEN 12
  • BXSL 6
  • Target Price
  • RGEN $172.67
  • BXSL $31.38
  • AVG Volume (30 Days)
  • RGEN 830.2K
  • BXSL 1.0M
  • Earning Date
  • RGEN 04-29-2025
  • BXSL 05-07-2025
  • Dividend Yield
  • RGEN N/A
  • BXSL 9.87%
  • EPS Growth
  • RGEN N/A
  • BXSL N/A
  • EPS
  • RGEN N/A
  • BXSL 3.14
  • Revenue
  • RGEN $650,429,000.00
  • BXSL $1,380,706,000.00
  • Revenue This Year
  • RGEN $13.93
  • BXSL $13.05
  • Revenue Next Year
  • RGEN $14.35
  • BXSL $7.20
  • P/E Ratio
  • RGEN N/A
  • BXSL $9.95
  • Revenue Growth
  • RGEN 4.88
  • BXSL 16.76
  • 52 Week Low
  • RGEN $102.97
  • BXSL $25.89
  • 52 Week High
  • RGEN $182.52
  • BXSL $34.64
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 44.98
  • BXSL 61.55
  • Support Level
  • RGEN $123.10
  • BXSL $29.07
  • Resistance Level
  • RGEN $135.47
  • BXSL $30.04
  • Average True Range (ATR)
  • RGEN 6.85
  • BXSL 0.52
  • MACD
  • RGEN -0.74
  • BXSL 0.32
  • Stochastic Oscillator
  • RGEN 19.54
  • BXSL 92.28

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.

Share on Social Networks: